The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.
The EU General Court handed a victory to Merck KGaA late last week, after rejecting a Swiss company’s trademark appeal.
While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.
Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
The speed of technological advancements in the life sciences industry is forcing patent lawyers to consider whether the norms they’re used to dealing with in the profession still apply.
The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.
The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.
Quinn Emanuel Urquhart & Sullivan has hired IP life sciences partner Colleen James from Mayer Brown.
Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.